Cargando…

Population Pharmacokinetic Modeling and Simulation of TQ-B3101 to Inform Dosing in Pediatric Patients With Solid Tumors

Background: TQ-B3101 is a novel kinase inhibitor currently in development for the treatment of advanced malignant solid tumor and relapsed or refractory ALK-positive anaplastic large cell lymphoma. Methods: A population pharmacokinetic model was developed using data collected from a Phase 1 study an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Fen, Wu, Huali, Bo, Yunhai, Lu, Ye, Pan, Hong, Li, Su, Lu, Qin, Xie, Simin, Liao, Harry, Wang, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804354/ https://www.ncbi.nlm.nih.gov/pubmed/35115931 http://dx.doi.org/10.3389/fphar.2021.782518

Ejemplares similares

Population pharmacokinetic analysis of TQ-B3203 following intravenous administration of TQ-B3203 liposome injection in Chinese patients with advanced solid tumors
por: Li, Xiaoqing, et al.
Publicado: (2023)

Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial
por: Lu, Shun, et al.
Publicado: (2023)

Simulation Training to Improve Informed Consent and Pharmacokinetic/Pharmacodynamic Sampling in Pediatric Trials
por: Burckhardt, Bjoern B., et al.
Publicado: (2020)

Population Pharmacokinetics of Caspofungin and Dose Simulations in Heart Transplant Recipients
por: Wu, Zheng, et al.
Publicado: (2022)

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
por: Huang, Weize, et al.
Publicado: (2022)

Rare top quark production in ATLAS ($t\bar{t}t\bar{t}$, $tqZ$, $tq\gamma$)
por: Sabatini, Paolo
Publicado: (2020)

Rare top quark production in ATLAS ($t\bar{t}t\bar{t}$, $tqZ$, $tq\gamma$)
por: Sabatini, Paolo
Publicado: (2021)

Population Pharmacokinetics and Model-Based Dosing Optimization of Teicoplanin in Pediatric Patients
por: Zhang, Tao, et al.
Publicado: (2020)

Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia
por: Gao, Xuan, et al.
Publicado: (2021)

Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment
por: Ye, Lingling, et al.
Publicado: (2022)

Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens
por: Suri, Ajit, et al.
Publicado: (2020)

First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults
por: Liu, Jingrui, et al.
Publicado: (2021)

Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2–17 years of age
por: Bradley, John S., et al.
Publicado: (2023)

Population Pharmacokinetics and Initial Dose Optimization of Sirolimus Improving Drug Blood Level for Seizure Control in Pediatric Patients With Tuberous Sclerosis Complex
por: Chen, Xiao, et al.
Publicado: (2021)

Bioactive Phenolics of the Genus Artemisia (Asteraceae): HPLC-DAD-ESI-TQ-MS/MS Profile of the Siberian Species and Their Inhibitory Potential Against α-Amylase and α-Glucosidase
por: Olennikov, Daniil N., et al.
Publicado: (2018)

External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients
por: Yang, Nan, et al.
Publicado: (2022)

Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients
por: Schmitz, Michael L., et al.
Publicado: (2020)

Prediction of a Therapeutic Dose for Buagafuran, a Potent Anxiolytic Agent by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Starting from Pharmacokinetics in Rats and Human
por: Yang, Fen, et al.
Publicado: (2017)

Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib
por: Chen, Lu, et al.
Publicado: (2022)

Migration and Proliferation Effects of Thymoquinone-Loaded Nanostructured Lipid Carrier (TQ-NLC) and Thymoquinone (TQ) on In Vitro Wound Healing Models
por: Alexander, Henna Roshini, et al.
Publicado: (2019)

Constituents, Pharmacokinetics, and Pharmacology of Gegen-Qinlian Decoction
por: Lu, Jing-Ze, et al.
Publicado: (2021)

Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients
por: Ayyoub, Amal, et al.
Publicado: (2016)

Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients
por: Dionisi, Marco, et al.
Publicado: (2021)

BK 3101: COVID-19-Infektion des HNO-Arztes ist Berufskrankheit, kein Arbeitsunfall
por: Michel, O.
Publicado: (2020)

Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria
por: de Kock, Miné, et al.
Publicado: (2018)

Translational Pharmacokinetic–Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose
por: Ballard, Jeanine E., et al.
Publicado: (2021)

Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing
por: Alasmari, Fawaz, et al.
Publicado: (2023)

Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics
por: Tan, Yan, et al.
Publicado: (2023)

Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens
por: Bundrant, Lu Ann, et al.
Publicado: (2018)

tqH FCNC in production and decay at ATLAS and CMS
por: Finelli, Kevin Daniel
Publicado: (2018)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients
por: Meibohm, Bernd
Publicado: (2022)

Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients
por: Maximova, Natalia, et al.
Publicado: (2022)

First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model
por: Chen, Jinliang, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

The Membrane Proteins Involved in Virulence of Cronobacter sakazakii Virulent G362 and Attenuated L3101 Isolates
por: Ye, YingWang, et al.
Publicado: (2015)

Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery
por: Lu, Cheng, et al.
Publicado: (2016)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

Microfluidic technology and simulation models in studying pharmacokinetics during pregnancy
por: Kammala, Ananth K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v5q0bttoti5a9u1di2jcl8j78i